Business
Cue Biopharma to Present at Upcoming Investor Conferences in November 2019
CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of
About this update from Cue Biopharma, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today that it will present at the Oncology Investor Conference on Wednesday, November 13, 2019 In New York and Stifel Healthcare Conference on Wednesday, November 20, 2019 in New York.\n Daniel Passeri, chief executive officer of Cue Biopharma, will provide an overview of the Immuno-STAT™ (Selective Targeting and Alteration of T cells) biologics platform for selective modulation of disease relevant T cells within the patient’s body. His presentation will also include an update on the company’s progress for the IL-2 based CUE-100 series with an emphasis on CUE-101, its lead clinical candidate. Additional conference details can be found below: Oncology Investor Conference Date and Time:November 13, 2019 at 1:20-1:40 p.m. ETLocation:Rockefeller Center 1155 6th Ave. New York, NY Stifel 2019 Healthcare Conference Date and Time:November 20, 2019 at 1:15-1:45 p.m. ETLocation:Lotte NY Palace Hotel 455 Madison Ave. New York, NYWebcast link:http://wsw.com/webcast/stifel18/cue/ About Cue BiopharmaCue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body to transform the treatment of cancer and autoimmune diseases. The company’s proprietary Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform is designed to harness the body’s intrinsic immune system without the need for ex vivo manipulation. Headquartered in Cambridge, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology treatments. For more information, visit www.cuebio.com and follow us on Twitter https://twitter.com/CueBiopharma. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looki...